Company intelligence / Profile preview

RetroLead

San Francisco, California, United Statesretrolead.itch.io ↗

Ownership: Private
Development stage: Other

Overview

Retro has multiple programs targeting cellular mechanisms of aging. Its lead small molecule autophagy activator ("rtrt42") aims to treat neurodegenerative disease by enhancing neuronal protein recycling. Human trials are expected to begin in Australia in late 2025. Additional programs include plasma-inspired therapies and both in vivo/ex vivo cellular reprogramming approaches. The company claims rapid progress compared to typical biotech timelines.

Therapeutic areas: OtherNeurology
Modalities: Small moleculeCell therapyPlasma-inspired therapyBiologic
Industry: Biotech

Partnerships

Multiply Labs ($85M agreement for automated cell therapy manufacturing)

Beyond the preview

Go deeper on RetroLead.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetroLead.

Explore the full profile